Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Impact of Cytogenetic Abnormalities On Outcome Among Patients with Relapsed/Refractory Multiple Myeloma Treated with Bortezomib: Adverse Effect of 1q21 (CKS1B) Amplification.

Hong Chang, Young Trieu, MSc, Connie Qi, Wei Xu, PhD, Donna E. Reece

Blood (2009) 114 (22): 2826.

https://doi.org/10.1182/blood.V114.22.2826.2826

Published: 2009

Journal Articles

Low Risk of Reactivation of Hepatitis B and Hepatic Injury in Multiple Myeloma (MM) Patients (pts) Undergoing Autologous Stem Cell Transplant (ASCT).

Christine Chen, MD, Young Trieu, MSc, Wei Xu, PhD, Suzanne Trudel, MD, Vishal Kukreti, MD, FRCPC, Peter Anglin, MD, Donna E. Reece, MD

Blood (2009) 114 (22): 3345.

https://doi.org/10.1182/blood.V114.22.3345.3345

Published: 2009

Journal Articles

Elderly Multiple Myeloma (MM) Patients (≥70 years) Can Safely Undergo Autologous Stem Cell Transplantation (ASCT) but Have Shorter Overall Survival Than Younger Patients (<70 years).

Carla Borgono, MSc, PhD, Young Trieu, MSc, Wei Xu, PhD, Donna E. Reece, MD, Suzanne Trudel, MD, Vishal Kukreti, MD, Peter Anglin, MD, Christine Chen, MD

Blood (2009) 114 (22): 3409.

https://doi.org/10.1182/blood.V114.22.3409.3409

Published: 2009

Journal Articles

Relationship of Treatment Effects On Hemoglobin and M-Protein Levels in Relapsed or Refractory Multiple Myeloma: Final Analysis of a Retrospective Chart Review Study.

Donna E. Reece, MD, Faraz Zaman, MD, Young Trieu, MSc, Giovanni Piza Rodriguez, MD, Bruno Teixeira, HBSc, Kim Yoong, BSc, Phm, Fernando Camacho, PhD, Richard K Plante, MSc

Blood (2009) 114 (22): 4892.

https://doi.org/10.1182/blood.V114.22.4892.4892

Published: 2009

Journal Articles

Sequencing Novel Agents in Relapsed/Refractory Multiple Myeloma: Use of Bortezomib-Based Therapy After Lenalidomide + Dexamethasone.

Donna E. Reece, MD, Young Trieu, MSc, Christine Chen, MD, Vishal Kukreti, MD, FRCPC, Wei Xu, PhD, Peter Anglin, MD, Suzanne Trudel, MD

Blood (2009) 114 (22): 1853.

https://doi.org/10.1182/blood.V114.22.1853.1853

Published: 2009

Journal Articles

Treatment of Relapsed and Refractory Multiple Myeloma in Patients with p53 Deletion.

Donna E. Reece, MD, Young Trieu, MSc, Hong Chang, MD, Wei Xu, PhD, Peter Anglin, MD, Christine Chen, MD, Vishal Kukreti, MD, Suzanne Trudel, MD, Joseph Mikhael, MD

Blood (2008) 112 (11): 1724.

https://doi.org/10.1182/blood.V112.11.1724.1724

Published: 2008

Journal Articles

The Impact of Cytogenetics on the Outcomes of Treatment with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma.

Nizar J Bahlis, MD, Kevin W. Song, Tommy Fu, Birgitte J Roland, MD, FCCMG, DABMG, Hong Chang, Doug Horsman, MD, PhD, Adnan Mansoor, MD, FRCPC, Christine Chen, MD, Esther Masih- Khan, Young Trieu, MSc, Helene Bruyere, MD, Douglas A. Stewart, MD, FRCPC, Donna E. Reece, MD

Blood (2008) 112 (11): 1731.

https://doi.org/10.1182/blood.V112.11.1731.1731

Published: 2008

Journal Articles

Steroid Refractoriness, but Not Rapidity of Response, to Induction Therapy Predicts for Outcome Post-Autologous Stem Cell Transplant (ASCT) in Patients (Pts) with Multiple Myeloma (MM)

Anca Prica, MD, Young Trieu, MSc, Wei Xu, PhD, Donna E. Reece, MD, Suzanne Trudel, MD, Vishal Kukreti, MD, Peter Anglin, MD, Christine Chen, MD

Blood (2008) 112 (11): 3315.

https://doi.org/10.1182/blood.V112.11.3315.3315

Published: 2008

Journal Articles

Loss of Chromosome 1p21 Band Is Associated with Disease Progression and Poor Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.

Hong Chang, MD, Connie Qi, MD, Allan Jiang, Wei Xu, PhD, Young Trieu, MSc, Donna E. Reece, MD

Blood (2008) 112 (11): 1702.

https://doi.org/10.1182/blood.V112.11.1702.1702

Published: 2008

Journal Articles

Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) Patients over Age 70.

Carla Borgono, PhD, Young Trieu, MSc, Wei Xu, PhD, Jacob Pendergrast, MD, Donna Reece, MD, Suzanne Trudel, MD, Joseph Mikhael, MD, Vishal Kukreti, MD, Christine I. Chen, MD

Blood (2007) 110 (11): 4952.

https://doi.org/10.1182/blood.V110.11.4952.4952

Published: 2007

Journal Articles

Weekly Cyclophosphamide and Alternate Day Prednisone: An Effective, Convenient and Well Tolerated Treatment for Relapsed Multiple Myeloma Following Autologous Stem Cell Transplant.

A. Keith Stewart, MD, Young Trieu, MSc, Suzanne Trudel, MD, Greg Pond, MSc, Joseph Mikhael, MD, Donna Reece, MD, Christine Chen, MD

Blood (2004) 104 (11): 4917.

https://doi.org/10.1182/blood.V104.11.4917.4917

Published: 2004

NARROW

Impact of Cytogenetic Abnormalities On Outcome Among Patients with Relapsed/Refractory Multiple Myeloma Treated with Bortezomib: Adverse Effect of 1q21 (CKS1B) Amplification.

Low Risk of Reactivation of Hepatitis B and Hepatic Injury in Multiple Myeloma (MM) Patients (pts) Undergoing Autologous Stem Cell Transplant (ASCT).

Elderly Multiple Myeloma (MM) Patients (≥70 years) Can Safely Undergo Autologous Stem Cell Transplantation (ASCT) but Have Shorter Overall Survival Than Younger Patients (<70 years).

Relationship of Treatment Effects On Hemoglobin and M-Protein Levels in Relapsed or Refractory Multiple Myeloma: Final Analysis of a Retrospective Chart Review Study.

Sequencing Novel Agents in Relapsed/Refractory Multiple Myeloma: Use of Bortezomib-Based Therapy After Lenalidomide + Dexamethasone.

Treatment of Relapsed and Refractory Multiple Myeloma in Patients with p53 Deletion.

The Impact of Cytogenetics on the Outcomes of Treatment with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma.

Steroid Refractoriness, but Not Rapidity of Response, to Induction Therapy Predicts for Outcome Post-Autologous Stem Cell Transplant (ASCT) in Patients (Pts) with Multiple Myeloma (MM)

Loss of Chromosome 1p21 Band Is Associated with Disease Progression and Poor Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.

Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) Patients over Age 70.

Weekly Cyclophosphamide and Alternate Day Prednisone: An Effective, Convenient and Well Tolerated Treatment for Relapsed Multiple Myeloma Following Autologous Stem Cell Transplant.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only